Age-expansion in HPV vaccination guideline was associated with increased HPV vaccine administration rates among adults aged 27 to 45 years

Published in the December issue of JAMA Health Forum, a research collaboration between the University of Texas Health Science Center at Houston (UTHealth Houston) School of Public Health and the University of Texas MD Anderson Cancer Center identified a significant increase in Human Papillomavirus (HPV) vaccine administration trends among adults aged 27 to 45 years following the age-expansion in the Advisory Committee on Immunization Practices (ACIP) HPV vaccine recommendation.

“在这一扩展的27至45岁年龄段中，先前接触HPV和临床特征的个体差异会影响HPV疫苗的有效性。证据支持以前未接触的老年人的疫苗功效，因此，这些人可以通过有效的共享临床决策从HPV疫苗中受益。以及休斯顿公共卫生学院UTHEALTH的社区健康。众所周知，HPV会引起宫颈，口咽，肛门，阴茎，阴道和外阴癌，并在美国每年大约45,000个新癌症诊断有关
中断的时间序列分析表明，2019年第二季度的ACIP指南年龄扩张更新与参加商业保险的男性和男性的HPV疫苗给药的显着增加有关。在种族和种族群体之间，年度管理率趋势相似。ACIP指南建议对9至26岁的人进行HPV疫苗接种，并在2019年扩大到包括27至45岁的年龄在27至45岁之间的人，以通过共同的临床决策接受疫苗。

“这些增加在2019年ACIP指南更新之前从未有资格接受HPV疫苗接种的出生队列中也很重要。这一发现表明，共同的临床决策可能对那些从不符合资格但有HPV疫苗的好处的人有效。” Suk说。这一共同的决策过程得到了最佳可用证据，证明谁可以从疫苗接种，个人的特征，价值和偏好以及临床医生的临床酌处权中受益。

This study impacts population health and individual healthcare, showing the significance of clinical guidelines and communication between clinicians and patients. This study suggests developing effective decision aids would be crucial to successfully implementing this updated ACIP guideline for maximizing the cancer prevention benefit in this age group.

撰稿人包括Kaiping Liao，PhD，CICI X. Bauer，PhD，MS，Catherine Basil和Meng Li，PhD，SCM。阅读全文这里.